Anthony H Nguyen

Array ( [id] => 7383070 [patent_doc_number] => 20040029272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-02-12 [patent_title] => 'Antisense modulation of perilipin expression' [patent_app_type] => new [patent_app_number] => 10/213796 [patent_app_country] => US [patent_app_date] => 2002-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32010 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0029/20040029272.pdf [firstpage_image] =>[orig_patent_app_number] => 10213796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6870567 [patent_doc_number] => 20030083257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-01 [patent_title] => 'Modified cDNA for high expression levels of factor VIII and its derivatives' [patent_app_type] => new [patent_app_number] => 10/210036 [patent_app_country] => US [patent_app_date] => 2002-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4000 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0083/20030083257.pdf [firstpage_image] =>[orig_patent_app_number] => 10210036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5865543 [patent_doc_number] => 20060099673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-05-11 [patent_title] => 'Novel recombinant gene expression method by stop codon suppression' [patent_app_type] => utility [patent_app_number] => 10/485397 [patent_app_country] => US [patent_app_date] => 2002-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 10425 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20060099673.pdf [firstpage_image] =>[orig_patent_app_number] => 10485397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7403590 [patent_doc_number] => 20040023904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-02-05 [patent_title] => 'Antisense modulation of PTPRA expression' [patent_app_type] => new [patent_app_number] => 10/210556 [patent_app_country] => US [patent_app_date] => 2002-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34056 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0023/20040023904.pdf [firstpage_image] =>[orig_patent_app_number] => 10210556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 168028 [patent_doc_number] => 07666674 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-02-23 [patent_title] => 'Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo' [patent_app_type] => utility [patent_app_number] => 10/484991 [patent_app_country] => US [patent_app_date] => 2002-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 22180 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/666/07666674.pdf [firstpage_image] =>[orig_patent_app_number] => 10484991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7401017 [patent_doc_number] => 20040019000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-29 [patent_title] => 'Polyalkyleneamine-containing oligomers' [patent_app_type] => new [patent_app_number] => 10/199585 [patent_app_country] => US [patent_app_date] => 2002-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 25106 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0019/20040019000.pdf [firstpage_image] =>[orig_patent_app_number] => 10199585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7357840 [patent_doc_number] => 20040014047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-22 [patent_title] => 'Antisense modulation of LIM domain kinase 1 expression' [patent_app_type] => new [patent_app_number] => 10/199199 [patent_app_country] => US [patent_app_date] => 2002-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31289 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0014/20040014047.pdf [firstpage_image] =>[orig_patent_app_number] => 10199199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 668530 [patent_doc_number] => 07094771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-08-22 [patent_title] => 'Pharmaceutical composition for boron neutron capture therapy containing triphenylboroxin' [patent_app_type] => utility [patent_app_number] => 10/194213 [patent_app_country] => US [patent_app_date] => 2002-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2235 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/094/07094771.pdf [firstpage_image] =>[orig_patent_app_number] => 10194213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 623673 [patent_doc_number] => 07138381 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-11-21 [patent_title] => 'Compositions containing nucleic acids and ligands for therapeutic treatment' [patent_app_type] => utility [patent_app_number] => 10/189360 [patent_app_country] => US [patent_app_date] => 2002-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 41 [patent_no_of_words] => 45642 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/138/07138381.pdf [firstpage_image] =>[orig_patent_app_number] => 10189360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6805043 [patent_doc_number] => 20030232437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-12-18 [patent_title] => 'Antisense modulation of VEGF-C expression' [patent_app_type] => new [patent_app_number] => 10/173718 [patent_app_country] => US [patent_app_date] => 2002-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32199 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0232/20030232437.pdf [firstpage_image] =>[orig_patent_app_number] => 10173718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7362452 [patent_doc_number] => 20040005292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-08 [patent_title] => 'Antisense modulation of SMRT expression' [patent_app_type] => new [patent_app_number] => 10/174014 [patent_app_country] => US [patent_app_date] => 2002-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30564 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0005/20040005292.pdf [firstpage_image] =>[orig_patent_app_number] => 10174014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 243336 [patent_doc_number] => 07589070 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-09-15 [patent_title] => 'Surface modification for improving biocompatibility' [patent_app_type] => utility [patent_app_number] => 10/170411 [patent_app_country] => US [patent_app_date] => 2002-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 10479 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/589/07589070.pdf [firstpage_image] =>[orig_patent_app_number] => 10170411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6847729 [patent_doc_number] => 20030166896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-04 [patent_title] => 'Base-modified enzymatic nucleic acid' [patent_app_type] => new [patent_app_number] => 10/170864 [patent_app_country] => US [patent_app_date] => 2002-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 10926 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20030166896.pdf [firstpage_image] =>[orig_patent_app_number] => 10170864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6808739 [patent_doc_number] => 20030198678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-10-23 [patent_title] => 'Polynucleotide compositions' [patent_app_type] => new [patent_app_number] => 10/164875 [patent_app_country] => US [patent_app_date] => 2002-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20427 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0198/20030198678.pdf [firstpage_image] =>[orig_patent_app_number] => 10164875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7394414 [patent_doc_number] => 20040038396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-02-26 [patent_title] => 'Spliceosome mediated RNA trans-splicing for correction of factor VIII genetic defects' [patent_app_type] => new [patent_app_number] => 10/360787 [patent_app_country] => US [patent_app_date] => 2002-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10227 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0038/20040038396.pdf [firstpage_image] =>[orig_patent_app_number] => 10360787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6861647 [patent_doc_number] => 20030092655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-15 [patent_title] => 'Delivery system for nucleic acids' [patent_app_type] => new [patent_app_number] => 10/158761 [patent_app_country] => US [patent_app_date] => 2002-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 11600 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0092/20030092655.pdf [firstpage_image] =>[orig_patent_app_number] => 10158761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6779188 [patent_doc_number] => 20030050270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-03-13 [patent_title] => 'Antisense modulation of Inhibitor-kappa B Kinase-beta expression' [patent_app_type] => new [patent_app_number] => 10/156610 [patent_app_country] => US [patent_app_date] => 2002-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25957 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0050/20030050270.pdf [firstpage_image] =>[orig_patent_app_number] => 10156610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7351440 [patent_doc_number] => 20040248831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-12-09 [patent_title] => 'Immunostimulatory oligodeoxynucleic molecules' [patent_app_type] => new [patent_app_number] => 10/478771 [patent_app_country] => US [patent_app_date] => 2003-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12020 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 3 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0248/20040248831.pdf [firstpage_image] =>[orig_patent_app_number] => 10478771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6861646 [patent_doc_number] => 20030092654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-15 [patent_title] => 'Antisense modulation of Inhibitor-kappa B Kinase-alpha expression' [patent_app_type] => new [patent_app_number] => 10/145857 [patent_app_country] => US [patent_app_date] => 2002-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0092/20030092654.pdf [firstpage_image] =>[orig_patent_app_number] => 10145857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6865103 [patent_doc_number] => 20030190629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-10-09 [patent_title] => 'Antisense modulation of PTTG1 expression' [patent_app_type] => new [patent_app_number] => 10/131544 [patent_app_country] => US [patent_app_date] => 2002-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25027 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0190/20030190629.pdf [firstpage_image] =>[orig_patent_app_number] => 10131544 [rel_patent_id] =>[rel_patent_doc_number] =>)